Tag: medical innovation

Prince Mario-Max Schaumburg-Lippe: Come Support The Waxman Cancer Research Foundation Gala on October 22nd!

Science and Celebration Unite at the Samuel Waxman Cancer Research Foundation Gala

A night of discovery, generosity, and global collaboration will illuminate New York as the Samuel Waxman Cancer Research Foundation hosts its 28th Annual Collaborating for a Cure fundraiser.

New Yorks PR Powerhouse Norah Lawlor has just informed us that on Wednesday, October 22, 2025, the Samuel Waxman Cancer Research Foundation will mark a remarkable chapter in its legacy of scientific progress and philanthropy. AND we want your support! The 28th Annual Collaborating for a Cure event, themed A Celebration of Breakthroughs, will take place at Apella, located at 450 East 29th Street in New York City. From 6:30 to 9:30 in the evening, supporters, scientists, and leaders from across industries will gather in a shared mission: to accelerate the discovery of cancer cures through innovation and unity.

This year’s gala will carry special meaning as it not only celebrates nearly five decades of transformative research funding but also unveils the Samuel Waxman Institute for Aging & Cancer. The newly established institute represents a pioneering effort in medical science, the first of its kind to study the intersection of aging and cancer in an integrated way. It embodies the Foundation’s enduring commitment to exploring new frontiers in cancer prevention and treatment by uniting brilliant minds across the globe.

All funds raised during the evening will be matched dollar-for-dollar through the Foundation’s partnership with The Mark Foundation for Cancer Research, effectively doubling the resources available to support groundbreaking scientific grants. The collaboration between these two organizations continues to expand the potential of translational research, ensuring that promising laboratory discoveries can evolve into real-world therapies faster than ever before.

The evening will also serve as a celebration of individuals whose contributions reflect the Foundation’s core values of leadership, compassion, and impact. Honorees include Jean Shafiroff, recognized as Philanthropist of the Year for her extensive charitable work and influence across numerous causes; Robert Wiener, Chairman Emeritus of Maxx Properties, also named Philanthropist of the Year for his longstanding commitment to philanthropy; and Dr. Jeffrey Settleman, Senior Vice President and Chief Scientific Officer for Oncology Research and Development at Pfizer, who will receive the prestigious Breakthrough Science Award for his exceptional contributions to advancing cancer research.

Over nearly three decades, the Collaborating for a Cure fundraiser has become one of New York’s most inspiring philanthropic evenings. Known for blending elegance with purpose, the event draws a distinguished audience from the worlds of science, business, fashion, and entertainment. Guests will enjoy an exquisite seated dinner accompanied by a program that highlights the latest achievements of SWCRF-supported researchers, showcasing how collaboration continues to redefine what is possible in cancer prevention, diagnosis, and treatment.

The Samuel Waxman Cancer Research Foundation stands as a model of sustained scientific partnership. Since its founding in 1976, the organization has awarded more than $120 million to over 200 researchers worldwide. Central to its success is the Foundation’s signature model, the Institute Without Walls, which fosters open collaboration among global investigators, encouraging them to share data, techniques, and discoveries in real time. This approach has dramatically accelerated the pace at which cancer research progresses, bridging disciplines and national boundaries in the pursuit of cures.

At the heart of the Foundation’s philosophy is the understanding that collaboration fuels discovery. Through the decades, SWCRF has consistently sought to fund innovative science that identifies and corrects abnormal gene functions responsible for cancer while minimizing treatment toxicity for patients. The organization’s impact extends far beyond traditional grantmaking, cultivating a global community of scientists united by the belief that cooperation is essential to eradicating cancer.

As the evening unfolds at Apella, attendees will be reminded of the enduring power of partnership — between scientists and philanthropists, between institutions and individuals, and between innovation and compassion. The setting, overlooking the East River, offers a fitting backdrop for a night that honors visionaries shaping the future of medicine.

The celebration’s timing also highlights an important evolution in the Foundation’s journey. With the formal introduction of the Samuel Waxman Institute for Aging & Cancer, the Foundation is ushering in a new era of scientific exploration. By bringing together researchers who specialize in both aging and oncology, this initiative seeks to understand how the biological processes of aging influence the development and progression of cancer. The insights generated through this work are expected to transform how scientists approach prevention strategies and therapeutic design for the years ahead.

The honorees each reflect the multidimensional spirit of the Foundation’s work. Jean Shafiroff, whose philanthropic reach spans healthcare, animal welfare, and education, continues to embody the intersection of generosity and advocacy. Robert Wiener’s influence as both a business leader and humanitarian reflects the vital role that private sector visionaries play in supporting life-changing research. Dr. Jeffrey Settleman’s leadership at Pfizer underscores how industry innovation and academic collaboration can work in concert to move science forward.

Each year, Collaborating for a Cure not only raises funds but also raises awareness of the profound impact that sustained scientific investment can achieve. The event’s atmosphere combines the refinement of a gala with the sense of urgency and optimism that accompanies groundbreaking research. Guests leave with a deeper understanding that progress in oncology is not measured solely in laboratory milestones but also in the lives extended and the families preserved through research-driven discovery.

The partnership between SWCRF and The Mark Foundation for Cancer Research serves as a model for modern philanthropy. By aligning missions and resources, these organizations demonstrate how cooperation between charitable and scientific entities can double the reach and impact of every contribution. Their shared vision ensures that funds raised in a single evening have the power to transform entire research portfolios and open new paths toward cancer cures.

Throughout the evening, attendees will have the opportunity to hear about recent advancements supported by SWCRF grants, each representing a step closer to transforming cancer from a life-threatening diagnosis into a manageable condition. From molecular insights into tumor resistance to precision therapies tailored to genetic profiles, the work funded by the Foundation exemplifies how sustained investment in science yields tangible hope.

As the 28th annual event approaches, anticipation builds among supporters who have witnessed the Foundation’s growth from a pioneering idea into a global force for scientific collaboration. The Samuel Waxman Cancer Research Foundation remains guided by its founder’s enduring belief that the cure for cancer will be discovered not by isolated efforts, but through collective determination and shared discovery.

For those wishing to join this celebration of progress and possibility, details and ticket information are available at www.waxmancancer.org/gala.

Dr. Samuel Waxman’s journey is defined by both scientific ambition and humanitarian vision. From his early days immersed in rigorous medical training to the founding of the Samuel Waxman Cancer Research Foundation and decades of global collaborations, his story is one of steady advancement toward the bold objective of eradicating cancer.

Born and raised in New York City, Samuel Waxman completed an undergraduate degree at Cornell University in 1957 and earned his M.D. at the State University of New York Downstate Medical Center in 1963. He then undertook residency and fellowship training at Mount Sinai Hospital in New York, where he would forge his career as an oncologist and hematologist.

In subsequent years he joined the faculty of the Icahn School of Medicine at Mount Sinai, rising to become the Zena and Michael A. Wiener Professor of Medicine (Cancer), Distinguished Service Professor of Medicine, Hematology and Medical Oncology, and Distinguished Service Professor of Oncological Sciences.

Even as the academic titles accumulated, Dr. Waxman’s attention stayed fixed on a key scientific frontier: the abnormal differentiation of cells that leads to leukemia and other cancers. He was among the first to champion “differentiation therapy” — a concept that instead of aiming merely to kill cancerous cells, seeks to restore them toward normal maturation.

In 1976, recognizing the critical need for flexible funding and cross‐institutional collaboration in cancer research, Dr. Waxman established the Samuel Waxman Cancer Research Foundation (SWCRF). The foundation was born out of a simple conversation with a donor who asked whether Dr. Waxman had ever thought of creating an organization to fund his work. From that moment, the foundation became his vehicle to marshal resources, build networks and drive research that crossed traditional institutional boundaries.

Under Dr. Waxman’s leadership the foundation adopted a philosophy he long held: science progresses fastest when investigators and laboratories with complementary strengths join forces. The SWCRF’s “Institute Without Walls” model embodies this by funding collaborations rather than isolated labs, enabling teams from North America, Europe and Asia to work in concert on cancer’s most intractable mysteries.

One of Dr. Waxman’s landmark achievements came in the treatment of acute promyelocytic leukemia (APL). Working with colleagues in China — notably at the Shanghai Institute of Hematology — he helped pioneer treatment regimens using all‐trans retinoic acid (ATRA) and arsenic trioxide. These therapies transformed APL from a near-certain fatal disease into one with survival rates above 90 percent.

Beyond leukemia, Dr. Waxman continued to apply differentiation‐based strategies, investigating how to correct abnormal gene functions, target regulatory proteins and even explore nutritional factors in cancer cell biology. His work linked vitamins such as A, B12 and folic acid to DNA synthesis and gene regulation, thus bridging basic biochemistry with clinical oncology.

Over the course of his career Dr. Waxman has authored more than 300 scientific papers, written chapters in textbooks on hematology and chemotherapy, and published books such as Differentiation Therapy and The Leukemia Cell. As founder and scientific director of SWCRF, he has overseen funding of tens of millions of dollars and fostered a global network of cancer researchers.

Equally important is Dr. Waxman’s role as mentor, connector and visionary. He has convened international conferences on differentiation therapy, set up honorary professorships (including at Shanghai Jiao Tong University) and guided young scientists into collaborative frameworks long before such models were common.

Dr. Waxman’s story is rooted in medicine yet shaped by global possibility. His early work in New York laboratories matured into partnerships that spanned oceans. His focus on differentiation therapy opened new pathways when cytotoxic chemotherapy seemed the only option. His foundation-building created infrastructure not only for his own laboratory but for research ecosystems that persist.

In recent years Dr. Waxman has held the titles of Professor Emeritus in Medicine, Hematology/Oncology and Oncological Sciences at Mount Sinai, while continuing active engagement in research and foundation work. His vision remains firmly on the future: therapies that are minimally toxic, personalized, gene‐function‐correcting, and globally accessible.

His legacy will persist well beyond his own lab: a generation of scientists seeing cancer not merely as a target to be destroyed but as a cellular programme to be re-educated; a network of collaborations crossing disciplinary and geographic borders; and therapies seeded from his foundational work that are now standard of care.

Dr. Samuel Waxman’s life is a testament to perseverance, innovation and the conviction that scientific progress is best achieved through cooperation rather than competition. His career exemplifies how a single patient‐centre orientation — that every cancer patient deserves the best possible future — can drive decades of inquiry, fund-raising, mentorship and global outreach.

In an era where the promise of cancer cure remains both urgent and complex, Dr. Waxman’s path reminds us that breakthroughs frequently come at the intersection of biology, collaboration and vision.

Samuel Waxman Cancer Research Foundation, Samuel Waxman Institute for Aging & Cancer, The Mark Foundation for Cancer Research, Jean Shafiroff, Robert Wiener, Jeffrey Settleman, Pfizer, Maxx Properties, Apella, New York City, Lawlor Media Group, Norah Lawlor, Collaborating for a Cure, A Celebration of Breakthroughs, Cancer Research, Oncology, Aging and Cancer, Cancer Prevention, Gene Function, Philanthropy, Global Science, Biomedical Innovation, Medical Research, New York Fundraisers, Health Leadership, Cancer Collaboration, Life Sciences, Precision Medicine, Molecular Biology, Cancer Treatment, Medical Innovation, Scientific Discovery, Global Health

Prince Mario-Max Schaumburg-Lippe: A Celebration of Breakthroughs: The 28th Waxman Collaboration for a Cure, Get Your Ticket Now!

PR Mogul Norah Lawlor just updated THE charity must-attend-event of the season. On a very special autumn evening in New York, leaders in science, philanthropy, and culture will gather at Apella on East 29th Street to honor innovation, compassion, and progress at the 28th Annual Waxman Collaboration for a Cure Gala. Hosted by the Samuel Waxman Cancer Research Foundation, this year’s celebration—fittingly themed A Celebration of Breakthroughs—marks nearly three decades of relentless pursuit toward curing cancer through collaboration and scientific excellence.

Set for October 22, 2025, the evening promises to blend elegance with purpose, uniting some of the most dedicated figures in medical research and charitable giving. The Samuel Waxman Cancer Research Foundation, established with the mission to eradicate cancer by funding collaborative and cross-disciplinary research, continues to stand as one of the most respected institutions in its field. Each year, the gala becomes a cornerstone of New York’s philanthropic calendar—a convergence of visionaries, researchers, and benefactors who share the belief that progress in science begins with unity of effort.

TICKETS: https://www.waxmancancer.org/waxman-gala-tickets/

Honoring Those Who Inspire Change

This year’s honorees reflect the Foundation’s wide-reaching ethos: compassion in action, leadership through service, and brilliance in discovery.

Jean Shafiroff, philanthropist, television personality, and author, will be recognized for her tireless dedication to charitable causes and her influential role in advancing health and humanitarian initiatives across New York and beyond. Her ability to bridge social influence with sincere advocacy for the underprivileged has made her a defining figure in modern philanthropy.

Robert Wiener, Chairman Emeritus of Maxx Properties, will be celebrated for his commitment to community enrichment and long-standing support of medical and scientific advancement. A respected figure in both business and charitable circles, Wiener exemplifies the leadership that fuels the Foundation’s work—steady, generous, and transformative.

Jeff Settleman, Ph.D., Senior Vice President and Chief Scientific Director of Oncology Research and Development at Pfizer, will be honored for his groundbreaking contributions to cancer research. His career, distinguished by a rare combination of academic rigor and visionary leadership, represents the very heart of the Foundation’s mission: to turn scientific collaboration into real-world cures.

Science, Philanthropy, and the Art of Collaboration

The Samuel Waxman Cancer Research Foundation has long championed the idea that collaboration, rather than competition, is the true engine of discovery. Since its founding, it has funded researchers across leading institutions worldwide, supporting projects that push the boundaries of understanding cancer’s origins and treatments. By fostering international partnerships, the Foundation ensures that breakthroughs are shared, accelerating the collective march toward prevention and cure.

The annual Collaboration for a Cure event is not merely a gala—it is a celebration of the scientific method as a shared human endeavor. Guests who attend find themselves immersed in an evening that unites the city’s cultural vitality with the gravity of scientific purpose. The conversations are as lively as the cause is profound, as doctors, donors, and advocates exchange ideas over candlelit tables overlooking the East River.

The elegant Apella venue, with its sleek architecture and luminous views, sets the perfect tone for an evening devoted to hope and progress. A reception filled with fine cuisine, heartfelt speeches, and moments of reflection underscores the meaning behind every research grant and discovery made possible by the Foundation’s supporters.

A Legacy of Impact

For nearly half a century, the Samuel Waxman Cancer Research Foundation has built a legacy rooted in collaboration. Its researchers have contributed to major advances in understanding genetic mutations, identifying new drug targets, and pioneering early detection methods that have changed lives across the globe. Each year, the Foundation reaffirms its mission through this event, where breakthroughs are not just celebrated—they are shared.

The Waxman Collaboration for a Cure embodies the Foundation’s core philosophy: that science and compassion must move forward together. Funds raised during the evening will directly support international research collaborations, young investigator programs, and cutting-edge studies that continue to push cancer research beyond boundaries of geography and discipline.

An Evening to Remember

As guests arrive on October 22nd, the atmosphere will reflect both the gravity of purpose and the joy of achievement. Scientists will stand shoulder-to-shoulder with philanthropists, united by a common goal—to make cancer not a life sentence, but a curable condition. Throughout the evening, stories of progress will intertwine with moments of gratitude, illuminating the ongoing power of shared discovery.

By the time the night draws to a close, applause will echo not just for the honorees, but for the collective spirit that has defined twenty-eight years of collaboration. The evening will reaffirm that breakthroughs do not belong to one individual or institution—they belong to all who believe in the power of partnership.

For those who attend, the 28th Waxman Collaboration for a Cure will stand as a testament to what can be achieved when intellect meets empathy, when science meets society, and when the pursuit of knowledge meets the deepest human desire—to heal.

Samuel Waxman Cancer Research Foundation, Waxman Collaboration for a Cure, Apella New York, Jean Shafiroff, Robert Wiener, Jeff Settleman, Pfizer Oncology, Norah Lawlor, Lawlor Media Group, New York Philanthropy, Cancer Research, Medical Innovation, Scientific Collaboration, Charity Galas, Health and Wellness, Cancer Awareness, Biomedical Breakthroughs, Research Funding, Global Health Initiatives, Nonprofit Events, Upper East Side Philanthropy, Medical Advancement, Cancer Cure Mission, Collaborative Science, NYC Charity Events, 2025 Fundraising Gala, Philanthropic Leadership, Biotechnology, Scientific Excellence, Community Impact, New York Society, Academic Partnerships

Prince Mario-Max Schaumburg-Lippe: Healing Joints Without the Knife: The Promise of Injectable Collagen Gels

For millions worldwide, joint pain is more than an inconvenience — it’s a daily battle that impacts movement, independence, and quality of life. Whether caused by sports injuries, accidents, or the slow grind of arthritis, damaged cartilage has long been one of medicine’s most frustrating challenges. Until recently, invasive surgery was often the only path to relief. But a quiet innovation from Germany is changing that narrative: an injectable collagen-based gel known as ChondroFiller.

The Problem of Cartilage Damage

Cartilage is the smooth, elastic tissue that cushions joints and allows bones to glide over one another without friction. Once injured, however, it has very little ability to repair itself. Unlike muscles or skin, cartilage lacks a blood supply that can deliver healing cells and nutrients. This means that even small tears or defects can grow into painful, chronic conditions.

For decades, doctors relied on procedures like microfracture surgery — deliberately drilling tiny holes into bone to stimulate new growth — or full joint replacement. While these methods help some patients, they come with long recovery times, significant risks, and in many cases, mixed long-term results.

Germany’s Answer: ChondroFiller

In 2013, a team of German researchers working with the Fraunhofer Institute introduced a different approach: an injectable collagen-based gel designed to mimic the natural environment of cartilage.

This innovation, originally known as ChondroFiller, could be applied through a minimally invasive procedure. Instead of removing damaged cartilage or replacing entire joints, surgeons could inject the gel directly into affected areas. Once inside the body, the gel provides a scaffold where new tissue can grow, supporting the body’s own natural repair process.

Unlike traditional surgery, which requires opening the joint, ChondroFiller needs only a small injection site — making it less traumatic for the patient, with faster recovery times.

Fact vs. Hype

In recent months, social media has reignited global buzz around ChondroFiller, touting it as a “brand-new miracle breakthrough.” The truth is more measured.

While the gel is an important step forward, it is not a cure-all. The injection is still a medical procedure that must be performed carefully, and it carries risks like any intervention — including allergic reactions and minor complications at the injection site. The treatment has been in use for over a decade, and its results are promising but not absolute. For some patients, it significantly reduces pain and restores mobility; for others, the outcomes are more modest.

Doctors caution that patients should view ChondroFiller as a valuable option within a spectrum of treatments rather than a magical replacement for surgery in all cases.

The Science Behind the Gel

Collagen, the protein that makes up connective tissues, is the backbone of the ChondroFiller gel. Scientists designed the injectable material to replicate the natural extracellular matrix of cartilage — essentially giving the body a template for rebuilding.

Once injected, the gel integrates with the joint environment. Over time, it allows cells to migrate into the scaffold and begin forming new cartilage-like tissue. The material is gradually resorbed, leaving behind healthier tissue in its place.

What makes this approach particularly compelling is its biocompatibility: instead of forcing the body to adapt to a foreign implant, it encourages the body to regenerate from within.

Patients on the Move Again

Early reports from patients in Germany and other countries where ChondroFiller is available highlight both its promise and its limits. Some describe returning to activities like jogging, hiking, or even competitive sports after struggling with years of pain. Others note reduced swelling and improved flexibility in daily tasks.

Still, not every patient experiences dramatic results. Some require follow-up procedures, while others eventually turn to more traditional surgeries if symptoms return. Doctors emphasize that outcomes depend heavily on factors such as age, overall health, size of the cartilage defect, and adherence to post-injection rehabilitation.

The Future of Cartilage Repair

ChondroFiller is only the beginning. Current research is exploring even more advanced solutions:

  • Biodegradable gels that mimic natural joint environments even more precisely.
  • Stem-cell infused scaffolds designed to accelerate true tissue regeneration.
  • 3D-printed cartilage structures customized to individual patients.

These innovations are showing promising early trial results, with some demonstrating near-complete restoration of cartilage in animal studies. However, scientists caution that most of these remain experimental and are not yet ready for everyday clinical use.

The ultimate vision? A future where damaged joints could be treated with a single injection — no surgery, no prosthetics — just the body rebuilding itself with a little scientific guidance.

A Balanced Outlook

For now, ChondroFiller represents a powerful middle ground: less invasive than surgery, more advanced than traditional therapies, and already in use across Europe. It does not eliminate the need for surgery in severe cases, nor does it guarantee success for everyone. But it is part of a growing wave of regenerative medicine that seeks not just to manage symptoms, but to truly heal.

For patients living with joint pain, that’s more than a medical development — it’s a reason to hope.